RecruitingPhase 4NCT06109155

The Effect of ACT and Tranexamic Acid on Bleeding in Cardiac Surgery

The Dose Effect of Activated Clotting Time and Tranexamic Acid on Bleeding in Adult Cardiac Surgery


Sponsor

Taichung Veterans General Hospital

Enrollment

150 participants

Start Date

Feb 8, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to the dose effect of tranexamic acid and the level of ACT on bleeding in adult cardiac surgery. The main questions it aims to answer are: 1. Does higher dose of tranexamic acid reduce the amount of bleeding and blood transfusion? 2. Does lower ACT level during cardiac surgery reduce the amount of bleeding and blood transfusion? Participants will divided into four groups which have different tranexamic acid dose and ACT level during cardiac surgery to see if there is any different in the amount of bleeding and blood transfusion.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • adult, cardiac surgery with cardiopulmonary bypass

Exclusion Criteria8

  • pregnant
  • emergency procedure
  • immune compromised
  • aortic surgery
  • end-stage renal disease
  • liver disease
  • critical status
  • incomplete clinical data

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTranexamic acid

tranexamic acid will be used in two different doses (50mg/kg vs 20mg/kg). the tranexamic acid pump will start from the begin of anesthesia until all dose is administrated.


Locations(2)

Taichung Veterans General Hospital

Taichung, Taiwan

Taichung Veterans General hospital

Taichung, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06109155


Related Trials